The Galien Foundation is honored to announce that Dr. Roch Doliveux, a distinguished leader in the global biopharmaceutical industry, will join the 2024 Prix Galien USA Awards Committee. Dr. Doliveux's remarkable career includes transforming UCB S.A. into a global leader in biopharmaceuticals during his tenure as CEO. He currently serves as Chairman of the Board at Oxford Biomedica and Pierre Fabre Group S.A., where his strategic vision continues to drive innovation in gene and cell therapy. With a deep commitment to patient-centric healthcare, Dr. Doliveux has also chaired the GLG Healthcare Institute and the Innovative Medicines Initiative (IMI), the world's largest healthcare public-private partnership. We look forward to the invaluable insights Dr. Doliveux will bring to the committee as we celebrate groundbreaking innovations in life sciences. #PrixGalienUSA #GalienFoundation #RochDoliveux #BiopharmaLeadership
The Galien Foundation
New York, NY 6,741 followers
A global foundation that fosters the open exchange of ideas to drive scientific innovation in medicine. #PrixGalien
About us
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives. The Foundation oversees and directs activities in for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. The Prix Galien has been introduced across Europe, Canada, the United States and is now the most prestigious award of its kind in 11 countries.
- Website
-
http://galienfoundation.org/
External link for The Galien Foundation
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1970
- Specialties
- medicine, healthcare, innovation, biopharmaceutical, pharmaceutical, clinical research, non profit, digital health, and medical technology
Locations
-
Primary
99 John Street
Suite 2502
New York, NY 10038, US
Employees at The Galien Foundation
Updates
-
The Galien Foundation is thrilled to announce that Dr. Marc Tessier-Lavigne, a pioneering neuroscientist and former President of Stanford University, will be joining the 2024 Prix Galien USA Awards Committee. Dr. Tessier-Lavigne's illustrious career spans academia and biotechnology, where he has significantly advanced our understanding of neurodegenerative diseases. His work has been recognized globally, earning him numerous prestigious awards, including the Gruber Neuroscience Prize. His leadership at Stanford also led to groundbreaking initiatives such as the creation of the Stanford Doerr School of Sustainability and the launch of the Stanford Institute for Human-Centered Artificial Intelligence (HAI). We are excited to see the profound insights Dr. Tessier-Lavigne will bring to our committee as we continue to honor innovations that are transforming healthcare. #PrixGalienUSA #GalienFoundation #MarcTessierLavigne #Neuroscience
-
-
The Galien Foundation is excited to announce that Dr. Stanley B. Prusiner, Nobel Laureate and Professor of Neurology at the University of California, San Francisco, will join the 2024 Prix Galien USA Awards Committee. Dr. Prusiner is renowned for discovering prions, a groundbreaking revelation that has transformed our understanding of neurodegenerative diseases. His continued leadership in neurological research and his commitment to advancing medical science make him an invaluable addition to our committee. We look forward to the insights Dr. Prusiner will bring as we celebrate the innovations that are shaping the future of healthcare. #PrixGalienUSA #GalienFoundation #StanleyPrusiner #Neurodegeneration
-
-
The Galien Foundation is proud to announce that Dr. Phillip A. Sharp, Nobel Laureate and Institute Professor at MIT Koch Institute for Integrative Cancer Research, will join the esteemed 2024 Prix Galien USA Awards Committee. Dr. Sharp’s pioneering work in RNA splicing has revolutionized molecular biology and continues to inspire innovation in biotechnology. His contributions extend far beyond the lab, shaping the future of cancer research and therapeutic development. We are eager to benefit from Dr. Sharp's unparalleled expertise as we honor groundbreaking advancements in the life sciences. #PrixGalienUSA #GalienFoundation #PhillipSharp #CancerResearch
-
-
Join us at the 2024 #PrixGalien USA as it returns to the prestigious halls of the American Museum of Natural History in New York on November 7! For more details on the illustrious history of The Galien Foundation, previous award winners, and this year's prize categories, please visit: https://lnkd.in/eu9CiH54
-
The Galien Foundation is honored to announce that Dr. Steven Lester MD, Chief Medical Officer of the Mayo Clinic and ASU MedTech Accelerator, will join the 2024 Prix Galien USA Awards Committee. Dr. Lester is a distinguished cardiologist with a deep commitment to advancing digital health and medical technology. His leadership at the Mayo Clinic and Arizona State University’s MedTech Accelerator has been pivotal in driving innovation in patient-centric care solutions. We are thrilled to have Dr. Lester's forward-thinking insights contributing to the recognition of excellence in life sciences. #PrixGalienUSA #GalienFoundation #DigitalHealth #StevenLester
-
-
The Galien Foundation is thrilled to announce that Dr. Cato T. Laurencin, University Professor and CEO of The Cato T. Laurencin Institute for Regenerative Engineering at the University of Connecticut, will serve as a Committee Member for the 2024 Prix Galien USA Awards. Dr. Laurencin is globally recognized as the founder of the field of regenerative engineering, with pioneering contributions to biomaterials science, nanotechnology, and stem cell research. His work has profoundly influenced advancements in tissue regeneration, shaping the future of medicine. We are honored to have Dr. Laurencin’s groundbreaking expertise guiding our celebration of innovation in life sciences. #PrixGalienUSA #GalienFoundation #RegenerativeEngineering #CatoLaurencin
-
-
The Galien Foundation is proud to announce that Dr. Robert S. Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), will be a Committee Member for the 2024 Prix Galien USA Awards. Dr. Langer is a pioneer in the field of biomedical engineering, known for his groundbreaking work in drug delivery systems and tissue engineering. His innovations have led to numerous medical advancements, impacting millions of lives worldwide. We are excited to have Dr. Langer’s visionary expertise guiding our celebration of life sciences excellence. #PrixGalienUSA #GalienFoundation #BiomedicalEngineering #RobertLanger
-
-
The Galien Foundation is honored to announce that Mary-Claire King, PhD, American Cancer Society Professor at the University of Washington, will be a Committee Member for the 2024 Prix Galien USA Awards. Dr. King is a visionary in the field of human genetics, best known for her groundbreaking discovery of the BRCA1 gene, which revolutionized our understanding of hereditary breast and ovarian cancer. Her pioneering work extends beyond cancer, influencing genetic research on schizophrenia, congenital disorders, and even human rights investigations. We are thrilled to have Dr. King’s unparalleled expertise and dedication to scientific innovation as part of our committee, helping us recognize the achievements of those who are transforming global healthcare. #PrixGalienUSA #GalienFoundation #GeneticResearch #MaryClaireKing
-
-
The Galien Foundation is honored to announce that Dr. Laurie Glimcher, MD, President and CEO of Dana-Farber Cancer Institute, will be a Committee Member for the 2024 Prix Galien USA Awards. Dr. Glimcher is a trailblazer in cancer research and immunology, recognized for her pioneering work in uncovering key regulators of immune responses. Her leadership at Dana-Farber has been transformative, steering groundbreaking initiatives that have shaped the future of cancer treatment and research. We are thrilled to welcome Dr. Glimcher's unparalleled expertise and commitment to innovation as we celebrate the achievements of those advancing global healthcare. #PrixGalienUSA #GalienFoundation #ScientificExcellence #LaurieGlimcher
-